Example: Heart Attack
Clinical Trials on Single Ventricular Heart
Total 0 results
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Medical Conditions
- COVID-19
- Burst Fracture
- Chlamydia Trachomatis Genital Infection
- HER2-Positive Metastatic Breast Cancer
- Hip Athroplasty Using M2a Magnum
- Longterm Effects
- Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST
- Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
- Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
- Neuromuscular Adaptations
- Pulmonary Function; Newborn, Abnormal
- Reasons for Detention Under Mental Health Act 1983
- Stage 2B Neuroblastoma
- Stage, Pancreatic Cancer
- View Full List
Sponsors and Collaborators
- Andrea Rossetti, MD
- Bernhoven Hospital
- Beyond Batten
- Département des Neurosciences cliniques, Service de Neurologie, Hôpitaux Universitaires de Genève
- EMO Biomedicine Corporation
- Genesis Limited
- King Fahd Medical Research Centre
- Laboratório de Genética Humana e Terapia Celular, Unesp - Assis
- Matthew Armstrong
- Merck spol.s.r.o., Czech Republic
- National Institute on Drug Abuse (NIDA)
- Norwich Clinical Research Associates Ltd.
- Universidade Federal de Ouro Preto
- View Full List
Drug Interventions
- 0.13% Benzalkonium Chloride
- 20 mg/kg TRU-016 and bendamustine
- Administration of dornase alfa
- Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
- Campath-1 H (Alemtuzumab)
- Fasinumab-matching placebo
- HMW PIB patch (NGMN+EE) (Treatment B) (Test)
- Placebo (Part I)
- Placebo as SC Injection
- Placebo to BI 1021958
- Ropivacaine Continuous Infusion Catheter
- autologous PBMCs
- glycopyrrolate, 4.0%
- View Full List
Conditions
Rare Diseases
Drug Interventions
Dietary Supplements
Sponsor/Collaborators
Locations